Benralizumab for previously treated severe nasal polyps [ID1659]
In development
Reference number: GID-TA10818
Expected publication date: TBC
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of benralizumab for previously treated severe nasal polyps. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
Following an update from the company that market benralizumab, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.